红色素形成刺激剂减少心力衰竭住院治疗:系统性审查和元分析
Karina V Bunting1,2, Otilia Tica1,3, Asgher Champsi1,2
1Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
European journal of heart failure
|March 2, 2026
概括
红色素形成刺激剂 (ESAs) 并没有显著减少慢性心力衰竭 (CHF) 的首次住院. 然而,ESA确实降低了复发性心血管疾病住院的数量,并改善了贫血患者的运动耐受性.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 贫血是慢性心力衰竭 (CHF) 患者的常见并发症,会对其功能状况和预后产生负面影响.
- 红色素形成刺激剂 (ESAs) 在减少心血管疾病住院治疗的有效性仍然不确定.
研究的目的:
- 系统评估ESA对CHF和贫血患者住院率,死亡率和功能能力的影响.
- 综合随机对照试验 (RCT) 的证据,以澄清ESA在治疗贫血性CHF患者中的作用.
主要方法:
- 进行了RCT的系统搜索,包括患有心血管疾病和贫血的成年患者,比较ESA与安慰剂或不接受治疗.
- 对14项涉及3128名参与者的试验数据进行了元分析,以评估住院,死亡率和不良事件等结果.
- 对大多数结局来说,证据质量被评为中度,试验间偏差风险可变.
主要成果:
- 欧元局没有显著降低首次CHF住院的风险 (Peto OR 0.93,95% CI 0.78-1.10).
- 在没有异质性的情况下,ESAs显著降低了CHF总住院次 (发生率比0.81,95% CI 0.73-0.90).
- 在全因死亡率或意外不良事件中没有发现显著差异. 欧洲体能度增加了血红蛋白水平,改善了运动耐受性和NYHA等级.
结论:
- 在轻度贫血的CHF患者中,ESA治疗可以减少复发性住院和提高功能能力,而不会增加不良事件.
- 在慢性心血管疾病管理中考虑ESA可能对患有贫血的患者有益,这些患者有高风险的重复入院.
相关概念视频
01:22Heart Failure Drugs: Diuretics
1.8K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
01:29Heart Failure II: Pathophysiology
2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
01:30Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641
01:22Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635